Electra Therapeutics

Electra Therapeutics is a clinical-stage biotechnology company. Electra is exploring breakthrough therapies for immunological diseases and cancer by targeting signal regulatory proteins (SIRP). The SIRP family consists of several proteins with varying roles across different immune cell types. Its immunology program leverages the differential expression of SIRP proteins on leukocytes to eliminate specific immune cell types. Its oncology platform utilizes the SIRPα/CD47 immune checkpoint signaling pathway to promote targeted destruction of tumor cells. The lead product, ELA026, is a monoclonal antibody specifically designed to treat severe inflammatory diseases associated with abnormal myeloid and T-cell activity. It selectively targets and depletes myeloid cells and T cells driving inflammation in the bloodstream without disrupting SIRPα/CD47 immune checkpoint function.